close


close
SYNVISC packaging
genzyme corporationresearchgenzyme websites
Information for patientsContact Us
HomeAbout SYNVISCClinical Info and ResearchReimbursement ResourcesOrdering SYNVISCPatient Education
SYNVISC

Home > Contact Us > Ask a Medical Question


Our Privacy Promise

We will not rent or sell your information to anyone. Your mailing address, email address, and any other personal information you provide voluntarily is kept confidential and will only be used to send you information about osteoarthritis and SYNVISC.

View our Privacy Policy

Ask a Medical Question
about SYNVISC®

To ask a question about FDA-approved SYNVISC, please fill in the required fields below (marked with an asterisk). This will enable us to respond to your question as quickly as possible. All information you provide will be kept confidential, in accordance with our Privacy Policy.

Once you have completed this form, type your question in the box provided, and click "Submit." The Genzyme Medical Information Group will reply to your request within five business days.




Important Safety Information

SYNVISC® (hylan G-F 20) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen. In clinical trials, the most commonly reported adverse events were transient local pain, swelling, and/or effusion in the injected knee. In some cases, these symptoms have been extensive. Other side effects such as rash have been reported rarely.

SYNVISC is contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the knee. Use caution when using SYNVISC in patients allergic to avian proteins, feathers, or egg products; who have evidence of venous or lymphatic stasis in the leg to be treated; or who have severe inflammation in the knee joint to be treated. Patients should be advised to avoid strenuous or prolonged weight-bearing activities after treatment. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC in children and in pregnant or lactating women have not been established. It is unknown whether SYNVISC is excreted in human milk.

View the Complete Prescribing Information for SYNVISC (PDF, 146k)